Clinical Trials and Evaluation Unit, University of Bristol Faculty of Medical and Veterinary Sciences, Bristol, UK
Centre for Surgical Research, School of Social and Community Medicine, University of Bristol, Bristol, UK.
BMJ Open. 2021 Jun 29;11(6):e044281. doi: 10.1136/bmjopen-2020-044281.
Surgery to remove the gallbladder (laparoscopic cholecystectomy (LC)) is the standard treatment for symptomatic gallbladder disease. One potential complication of gallbladder disease is that gallstones can pass into the common bile duct (CBD) where they may remain dormant, pass spontaneously into the bowel or cause problems such as obstructive jaundice or pancreatitis. Patients requiring LC are assessed preoperatively for their risk of CBD stones using liver function tests and imaging. If the risk is high, guidelines recommend further investigation and treatment. Further investigation of patients at low or moderate risk of CBD stones is not standardised, and the practice of imaging the CBD using magnetic resonance cholangiopancreatography (MRCP) in these patients varies across the UK. The consequences of these decisions may lead to overtreatment or undertreatment of patients.
We are conducting a UK multicentre, pragmatic, open, randomised controlled trial with internal pilot phase to compare the effectiveness and cost-effectiveness of preoperative imaging with MRCP versus expectant management (ie, no preoperative imaging) in adult patients with symptomatic gallbladder disease undergoing urgent or elective LC who are at low or moderate risk of CBD stones. We aim to recruit 13 680 patients over 48 months. The primary outcome is any hospital admission within 18 months of randomisation for a complication of gallstones. This includes complications of endoscopic retrograde cholangiopancreatography for the treatment of gallstones and complications of LC. This will be determined using routine data sources, for example, National Health Service Digital Hospital Episode Statistics for participants in England. Secondary outcomes include cost-effectiveness and patient-reported quality of life, with participants followed up for a median of 18 months.
This study received approval from Yorkshire & The Humber - South Yorkshire Research Ethics Committee. Results will be submitted for publication in a peer-reviewed journal.
ISRCTN10378861.
切除胆囊的手术(腹腔镜胆囊切除术(LC))是治疗有症状胆囊疾病的标准治疗方法。胆囊疾病的一种潜在并发症是胆结石可能进入胆总管(CBD),在那里它们可能处于休眠状态,自行排入肠道,或引起阻塞性黄疸或胰腺炎等问题。需要进行 LC 的患者在术前会根据肝功能检查和影像学检查来评估其 CBD 结石的风险。如果风险较高,指南建议进一步检查和治疗。对于 CBD 结石低或中度风险的患者,进一步检查并未标准化,并且在这些患者中使用磁共振胰胆管成像(MRCP)对 CBD 进行成像的做法在英国各地有所不同。这些决策的后果可能导致对患者的过度治疗或治疗不足。
我们正在英国进行一项多中心、实用、开放性、随机对照试验,同时进行内部试点阶段,以比较在接受紧急或择期 LC 的有症状胆囊疾病且 CBD 结石低或中度风险的成年患者中,术前使用 MRCP 与预期管理(即无术前成像)的有效性和成本效益。我们的目标是在 48 个月内招募 13680 名患者。主要结局是随机分组后 18 个月内因胆结石并发症而住院的任何情况。这包括内镜逆行胰胆管造影术治疗胆结石的并发症和 LC 的并发症。这将通过常规数据源确定,例如英格兰参与者的国家卫生服务数字医院发病统计数据。次要结局包括成本效益和患者报告的生活质量,参与者的随访中位数为 18 个月。
该研究得到了约克郡和亨伯南-南约克郡研究伦理委员会的批准。结果将提交给同行评议的期刊发表。
ISRCTN8161645。